Supreme Court Declines CareDx Appeal in Natera Ad Dispute
The U.S. Supreme Court refused to hear CareDx's appeal in its false-advertising clash with genetic testing rival Natera.
The U.S. Supreme Court has rejected an appeal from CareDx, leaving intact a lower court ruling in a false-advertising lawsuit brought by genetic testing company Natera, Inc. The high court's decision not to take up the case marks a significant legal setback for CareDx in a dispute centered on marketing claims made in the competitive transplant diagnostics market.
The case pits two major players in the organ transplant monitoring space against each other, with Natera alleging that CareDx made misleading advertising claims about its products. By declining to hear CareDx's appeal, the Supreme Court effectively allows the previous court's findings to stand, giving Natera a procedural victory without the justices weighing in on the underlying merits.
Read more Novo Nordisk Sues Eli Lilly Over Allegedly Deceptive GLP-1 Ads →
The Supreme Court routinely declines the vast majority of petitions it receives each term, and its refusal to grant certiorari does not constitute an opinion on the legal questions raised. Nevertheless, for CareDx, the door to federal high-court relief is now closed, forcing the company to contend with whatever judgment or proceedings remain at the lower court level.
The false-advertising dispute underscores intensifying competition in the molecular diagnostics sector, where companies like Natera and CareDx compete aggressively for market share in kidney and organ transplant surveillance testing. Legal battles over product claims are increasingly common as rival firms seek both competitive advantage and reputational standing with physicians and health systems.
Continue reading at Yahoo Finance.
